AGENDA

Programme will be added once finalised.
Check the program of the previous edition HERE

DAY 1

Thursday, 22 May 2025

8h15

Welcome coffee and registration

8h45

Welcome address

- Plenary

Chairman

Charles Wolf

Country Lead Sanofi

Sanofi - France

9h00

Current Landscape and Pipeline Trends in Cell & Gene Therapy

Gavin Vuddamalay

Head of Scientific Affairs & Business Intelligence

MabDesign - France

9h15

Keynote lecture: Pioneering Research and Applications in iPS cells

- Plenary

Chairman

9h15

Organoids vs human pluripotent stem cells for cell based therapy

Ludovic Vallier

Einstein Professor for stem Cells in Regenerative Therapies

Berlin Institute of Health - Germany

9h45

Track 1: Pioneering Research and Applications in iPS cells

- Plenary

Chairman

9h45

Translation of pluripotent stem cell-based liver cell therapy into the clinic from an industrial perspective

Tuan Huy Nguyen

Co-Founder, President, and Chief Science Officer

GoLiver Therapeutics - France

10h05

Established new immunodeficient large animal model for receiving human induced pluripotent stem cell-derived hematopoietic grafts.

Mathias Brunet-Manquat

PhD Student

Etablissement Français du Sang / Centre de Recherche de Saint Antoine - France

10h25

Cross-Cutting Talk

- Plenary

Chairman

10h25

Liver-Directed Gene Therapy Using Immune-Shielded Lentiviral Vectors for Methylmalonic Acidemia

Julianne Smith

Chief Development Officer

Genespire - Italy

10h45

Coffee break - Exhibition Hall

11h15

Roundtable: Lessons Learned: Insights from Biotechs Post-Fundraising

- Plenary

Animated by MabDesign

Olivier Nègre

Chief Scientific Officer

Smart Immune, France

Philippe Chambon

Chairman, Ceo and founder

EG427, France

Rodolphe Clerval

CEO

Coave Therapeutics - France

Raphaëlle Kieffer

Head of Innovation Funding

MabDesign - France

Geoffrey Richard

Head of Private Finance

MabDesign - France

12h15

Lunch - Exhibition Hall - B2B Meetings

13h00

Roundtable: Rapid Sterility - Current Developments, Challenges and Emerging Perspectives

- Plenary

Animated by bioMérieux

Hélène Nègre

Pharmaceutical Affairs Director

CELLforCURE by Seqens, France

Guillaume Churlaud

Pharmacist, ATMP QC Manager

EFS, France

Marc Meichenin

chief scientific officer

Clean Cells, France

Caroline Kassim

R&D Biosciences Manager

bioMérieux, France

Guillaume Devun

Business Manager Rapid Methods

bioMérieux, France

14h00

Keynote lecture: Viral and Non-Viral Vectors : target optimization

- Plenary

Chairman

14h00

Development and validation of an intravenous AAV gene therapy for mucopolysaccharidosis type IIIB in mouse and dog model of the pathology

Francoise Piguet

Head of the innovation unit GENOV

Institut du Cerveau - France

14h30

Track 2: Viral and Non-Viral Vectors : target optimization

- Plenary

Chairman

14h30

Developping AAVs with improved safety and efficacy in neuromuscular disorders

Stephane Degove

CEO

Atamyo - France

14h50

Improving AAV Vectors efficacy and specificity via chemical conjugation

Lolita Petit

CSO

Coave Therapeutics - France

15h10

Development of targeted LNP

Catalina Bordeianu

Laboratory Head, Principal Scientist

Sanofi - France

15h30

Dynamic Carriers for RNA Delivery and Genome Editing

Ernst Wagner

Professor of Pharmaceutical Biotechnology

Ludwig-Maximilians-Universität (LMU) - Germany

Center of Nanoscience in Munich - Germany

15h50

Accelerating Non-Viral Delivery: From Custom Components to Scalable Manufacturing Solutions

Philippe Clavel

CEO

Curapath - Spain

16h10

Scaling Up Cell and Gene Therapy Biomanufacturing with high quality raw materials and dedicated solutions

Mourad Ferhat

Regional Director (France/BeneLux Region)

Acrobiosystems - Netherlands

16h20

Coffe Break - Exhibition Hall - B2B Meetings

17h00

Breakthrough innovation session

- Plenary

Chairman

17h00

Using mechanistic PK model to predict the human dose for AVM-022 gene therapy

Matthias Machacek

Managing Director

LYO-X - Switzerland

17h10

From design to clinic: Supporting advances in Cell and Gene Therapies through tailored plasmid manufacturing services

Nicolas Laugier

Sales

RD-Biotech - France

17h20

GREAT: Gene Recombination Along with Transposase

Francois Cherbonneau

CEO and Co-founder

QUIDDITAS - Belgium

17h30

Combination of TCR-deficient CAR-Tregs and non-mitogenic antiCD3 to promote transplant tolerance

Tifanie Blein

PhD Student

Institut Necker Enfants Malades - France

17h40

Tissue engineering based on human pluripotent stem cells for the treatment of Retinitis Pigmentosa and Age-related macular degeneration: a journey from preclinical to first clinical data

Karim Ben M’Barek

Research Scientist

I-Stem - France

17h50

Label free optical characterization of vector loading

Matthieu Greffet

President

UNVEIL - France

18h00

Innovative Human iPSC-Derived Retinal Organoid Model for AAV Gene Therapy Development

Amy Mawdesley

Business Development Manager

Newcells Biotech - United Kingdom

17h30

A Beating Cardiac Fibrosis on Chip Model to Predict the Efficacy of Drugs and Advanced Therapies

Erika Ferrari

Commercial Science Leader

BiomimX - Italy

18h30

Cocktail Reception hosted by Sanofi

- Plenary

19h45

End of day 1

DAY 2

Friday, 23 May 2025

8h30

Welcome coffee and registration

9h00

Track 3: Exploring the Future of CARs & TILs - session 1

- Plenary

Chairman

9h00

Nonclinical development of in vivo CAR-T for autoimmune diseases

Franck Chanut

Head of Preclinical Safety R&D Project France

Sanofi - France

9h20

The Dark Genome is a source of highly specific antigens for cancer immunotherapy

Michael Saitakis

Director, Immunotherapy

Mnemo Therapeutics - France

9h40

Alaya.bio: a polymeric gene delivery platform for in vivo CAR-T treatments

Renaud Vaillant

Founder and President

Alaya.bio - France

10h00

From Sequence to Cure: DNA/RNA Analytics in Cell and Gene Therapy

Sergey Yakushev

Head of Genetic Analysis

Microsynth - Switzerland

10h10

Coffee break - Exhibition Hall

11h00

Track 3: Exploring the Future of CARs & TILs - session 2

- Plenary

Chairman

11h00

Antigen selective CAR-T applied to autoimmune diseases

Christian Jorgensen

Director

IRMB - Institute for Regenerative Medicine & Biotherapy - France

11h20

Implementing co-creation with patients in the context of a Phase II pragmatic clinical trial to optimize treatment with TILs therapy

Emma Gillanders

Project Manager - Cancer Survivorship Group

Institut Gustave Roussy - France

11h40

How to address complexity? The point of view of the biomanufacturing partner

Célia Mercier

Business Developer EFS Bioproduction

EFS - France

12h10

Lunch - Exhibition Hall - B2B Meetings

Revolutionising Cell and Gene Therapy: Accelerating CAR T Processes and Drug Development

- Plenary

Chairman

13h00

24 Hour CAR T Process

Jerome Cabeau

Business Development Manager for Cell & Gene Therapy

Thermo Fisher Scientific - France

13h30

Accelerator Drug Development Initiatives

Pavithra Singaravelu

Senior Business Development Executive - Biotech Solutions

Thermo Fisher Scientific - France

14h00

Keynote lecture: Exploring the Future of CARs & TILs

- Plenary

Chairman

10h00

Title to be announced

14h00

A new class of tumor targets for next-generation cancer immunotherapies

Sebastian Amigorena

Team Leader

Institut Curie - France

14h30

Track 4: Gene Editing: Innovations, Challenges, and Applications

- Plenary

Chairman

14h30

The challenges of gentically modified Treg cell therapy in autoimmune disease and transplantation

Makoto Miyara

Professor

AP-HP, Assistance Publique - Hôpitaux de Paris - France

14h50

Advanced TALEN gene-editing for overcoming barriers to the success of CAR-T cells in solid tumors